{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:41:22Z","timestamp":1778575282550,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ad.2023.07.016","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T11:48:02Z","timestamp":1690372082000},"page":"T802-T811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["[Translated article] Moderate to Severe Psoriasis in Older Adults: Recommendations on Management From the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV)"],"prefix":"10.1016","volume":"114","author":[{"given":"J.","family":"Mataix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Belinch\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Ruiz Carrascosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"de la Cueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2023.07.016_bib0280","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/jdv.12688","article-title":"Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry","volume":"29","author":"Medina","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.07.016_bib0285","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1203475419897578","article-title":"Biologic treatment in elderly patients with psoriasis: a systematic review","volume":"24","author":"Sandhu","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2023.07.016_bib0290","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials","volume":"148","author":"Garcia-Doval","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2023.07.016_bib0295","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10522-014-9514-3","article-title":"Innate immunesenescence: underlying mechanisms and clinical relevance","volume":"16","author":"Hazeldine","year":"2015","journal-title":"Biogerontology"},{"key":"10.1016\/j.ad.2023.07.016_bib0300","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/rheumatology\/kep291","article-title":"Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients","volume":"48","author":"K\u00f6ller","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ad.2023.07.016_bib0305","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00002512-200219110-00003","article-title":"Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options","volume":"19","author":"Yosipovitch","year":"2002","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ad.2023.07.016_bib0310","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40266-020-00790-x","article-title":"Optimizing the treatment of moderate-to-severe psoriasis in older adults","volume":"37","author":"Shary","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ad.2023.07.016_bib0315","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40266-014-0156-6","article-title":"Managing moderate-to-severe psoriasis in the elderly","volume":"31","author":"Balato","year":"2014","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ad.2023.07.016_bib0320","unstructured":"Calidad de Vida y Psoriasis; 2016. Available from: https:\/\/aedv.es\/wp-content\/uploads\/2016\/07\/Calidad-de-vida-y-psoriasis.pdf [cited 16.11.21]."},{"key":"10.1016\/j.ad.2023.07.016_bib0325","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ad.2019.02.009","article-title":"Instrumentos para la valoraci\u00f3n de los resultados percibidos por el paciente con psoriasis en Espa\u00f1a: revisi\u00f3n sistem\u00e1tica de la literatura","volume":"110","author":"Liz\u00e1n","year":"2019","journal-title":"Actas Dermo-Sifiliogr"},{"key":"10.1016\/j.ad.2023.07.016_bib0330","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris \u2013 Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.07.016_bib0335","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2133.2006.07617.x","article-title":"The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease","volume":"156","author":"Basra","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.07.016_bib0340","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2318-12-46","article-title":"Frail elderly patients\u2019 experiences of information on medication. A qualitative study","volume":"12","author":"Modig","year":"2012","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.ad.2023.07.016_bib0345","unstructured":"Grupo de trabajo de vacunaci\u00f3n frente a herpes z\u00f3ster de la Ponencia de Programa y Registro de Vacunaciones. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad; Mar 2021 [07\/2022]. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/programasDeVacunacion\/docs\/HerpesZoster_RecomendacionesVacunacion.pdf [cited 17.11.21]."},{"key":"10.1016\/j.ad.2023.07.016_bib0350","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/1203475420914622","article-title":"Incidence, clinical features management, and prevention of herpes zoster in patients receiving antitumor necrosis factor therapy: a clinical review","volume":"24","author":"Kim","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2023.07.016_bib0355","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of Herpes Zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ad.2023.07.016_bib0360","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2023.07.016_bib0365","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ad.2023.07.016_bib0370","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000338691","article-title":"Herpes zoster in patients treated with biologicals","volume":"224","author":"Failla","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2023.07.016_bib0375","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jbspin.2013.07.009","article-title":"Risk of herpes\/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis","volume":"81","author":"Che","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ad.2023.07.016_bib0380","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/14712598.2018.1504016","article-title":"An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly","volume":"18","author":"Di Lernia","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ad.2023.07.016_bib0385","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.07.016_bib0390","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jdv.15324","article-title":"Gender and age significantly determine patient needs and treatment goals in psoriasis \u2013 a lesson for practice","volume":"33","author":"Maul","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.07.016_bib0395","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjd.19665","article-title":"Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups","volume":"184","author":"van Winden","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.07.016_bib0400","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/1346-8138.12653","article-title":"Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis","volume":"41","author":"Hayashi","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2023.07.016_bib0405","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40257-019-00468-0","article-title":"Treatment of Medicare patients with moderate-to-severe psoriasis who cannot afford biologics or apremilast","volume":"21","author":"Natsis","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2023.07.016_bib0410","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ad.2023.07.016_bib0415","first-page":"78","article-title":"Prevalence of chronic renal disease in Spain: results of the EPIRCE study","volume":"30","author":"Otero","year":"2010","journal-title":"Nefrologia"},{"key":"10.1016\/j.ad.2023.07.016_bib0420","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2340\/00015555-1719","article-title":"Efficacy and safety of systemic treatments for psoriasis in elderly patients","volume":"94","author":"Piaserico","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.07.016_bib0425","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ad.2013.01.003","article-title":"Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Carretero","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.07.016_bib0430","doi-asserted-by":"crossref","first-page":"367475","DOI":"10.1155\/2012\/367475","article-title":"The safety of systemic treatments that can be used for geriatric psoriasis patients: a review","volume":"2012","author":"Wong","year":"2012","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.ad.2023.07.016_bib0435","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14740338.2023.2173171","article-title":"Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: Focus on elderly patients","volume":"22","author":"Megna","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ad.2023.07.016_bib0440","unstructured":"Informe de Posicionamiento terap\u00e9utico (IPT) de brodalumab [09\/2021]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-brodalumab-Kyntheum-psoriasis.pdf [cited 22.9.21]."},{"key":"10.1016\/j.ad.2023.07.016_bib0445","unstructured":"Informe de Posicionamiento terap\u00e9utico (IPT) de guselkumab [09\/2021]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-guselkumab-Tremfya-psoriasis.pdf [cited 22.9.21]."},{"key":"10.1016\/j.ad.2023.07.016_bib0450","unstructured":"Informe de Posicionamiento terap\u00e9utico (IPT) de ixekixumab [09\/2021]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-ixekizumab-Taltz-psoriasis.pdf [cited 22.9.21]."},{"key":"10.1016\/j.ad.2023.07.016_bib0455","unstructured":"Informe de Posicionamiento terap\u00e9utico (IPT) de risankizumab [09\/2021]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT_7-2020-risankizumab-Skyrizi.pdf?x71164 [cited 22.9.21]."},{"key":"10.1016\/j.ad.2023.07.016_bib0460","unstructured":"Informe de Posicionamiento terap\u00e9utico (IPT) de secukinumab [09\/2021]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-secukinumab-Cosentyx.pdf [cited 22.9.21]."},{"key":"10.1016\/j.ad.2023.07.016_bib0465","unstructured":"Informe de Posicionamiento terap\u00e9utico (IPT) de tildrakizumab [09\/2021]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-tildrakizumab-Ilumetri-psoriasis-placas.pdf?x12095 [cited 22.9.21]."},{"key":"10.1016\/j.ad.2023.07.016_bib0470","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/jamadermatol.2020.2311","article-title":"Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review","volume":"156","author":"Van Winden","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2023.07.016_bib0475","first-page":"846","article-title":"Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis","volume":"14","author":"Garber","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2023.07.016_bib0480","series-title":"30TH EADV Congress","article-title":"GEriatric Psoriasis PAtterns (GEPPA): a multicentre retrospective cohort study on disease and treatment patterns in older adults with psoriasis","author":"Ter Haar","year":"2021"},{"key":"10.1016\/j.ad.2023.07.016_bib0485","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jdv.15139","article-title":"Elderly psoriatic patients under biological therapies: an Italian experience","volume":"33","author":"Ricceri","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.07.016_bib0490","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/ced.14258","article-title":"Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period","volume":"45","author":"Megna","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2023.07.016_bib0495","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/09546634.2020.1809623","article-title":"Elderly patients with psoriasis: long-term efficacy and safety of modern treatments","volume":"33","author":"Bakirtzi","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2023.07.016_bib0500","doi-asserted-by":"crossref","first-page":"adv00316","DOI":"10.2340\/00015555-3678","article-title":"Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis","volume":"100","author":"Phan","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.07.016_bib0505","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","article-title":"Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies","volume":"35","author":"K\u00f6rber","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ad.2023.07.016_bib0510","first-page":"e152","article-title":"Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period","volume":"34","author":"Megna","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.07.016_bib0515","unstructured":"Ustekinumab Summary of Product Characteristics [09\/2021]. Available from: https:\/\/cima.aemps.es\/cima\/pdfs\/ft\/108494004\/FT_108494004.pdf [cited 22.9.21]."},{"key":"10.1016\/j.ad.2023.07.016_bib0520","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40257-013-0053-5","article-title":"Safety and tolerability of tumor necrosis factor-\u03b1 inhibitors in psoriasis: a narrative review","volume":"15","author":"Semble","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2023.07.016_bib0525","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ad.2018.02.015","article-title":"Management of moderate to severe psoriasis in routine clinical practice in Spanish hospitals","volume":"109","author":"L\u00f3pez-Estebaranz","year":"2018","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.ad.2023.07.016_bib0530","doi-asserted-by":"crossref","first-page":"547","DOI":"10.12968\/bjon.2020.29.10.547","article-title":"Safe and effective use of phototherapy and photochemotherapy in the treatment of psoriasis","volume":"29","author":"Campbell","year":"2020","journal-title":"Br J Nurs"},{"key":"10.1016\/j.ad.2023.07.016_bib0535","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1080\/09546634.2021.1962000","article-title":"Efficacy and safety of dimethylfumarate in elderly psoriasis patients: a multicentric Italian study","volume":"33","author":"Ricceri","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2023.07.016_bib0540","unstructured":"Dimetilfumarato FT. Available from: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/113837001\/FT_113837001.pdf [cited 22.9.21]."},{"key":"10.1016\/j.ad.2023.07.016_bib0545","unstructured":"Apremilast FT. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_es.pdf [cited 22.9.21]."},{"key":"10.1016\/j.ad.2023.07.016_bib0550","unstructured":"Ministerio de Sanidad, consumo y bienestar social. Vacunaci\u00f3n en poblaci\u00f3n adulta. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/programasDeVacunacion\/docs\/Vacunacion_poblacion_adulta.pdf [cited 22.9.21]."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023006245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023006245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:31:50Z","timestamp":1762075910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731023006245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0001731023006245"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2023.07.016","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Moderate to Severe Psoriasis in Older Adults: Recommendations on Management From the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV)","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.05.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}